Maozhi Liang

机构：Sichuan University, West China Hospital of Sichuan University

发表论文 31 篇 · 总被引 863 次 · h-index 9

代表论文

• Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer (2020 · Nature Medicine · 被引 546)
• Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study (2016 · Lung Cancer · 被引 38)
• Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel TPO ‐R Agonist, in Healthy Individuals (2017 · Basic & Clinical Pharmacology & Toxicology · 被引 31)
• A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer. (2018 · Journal of Clinical Oncology · 被引 30)
• Pharmacokinetics and Bioequivalence of Two Formulations of Febuxostat 40-Mg and 80-Mg Tablets: A Randomized, Open-Label, 4-Way Crossover Study in Healthy Chinese Male Volunteers (2016 · PLoS ONE · 被引 14)
• Abstract CT133: A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer with PD-L1 expression (2018 · Cancer Research · 被引 9)